Research programme: siRNA hepatitis therapeutics - Alnylam Pharmaceuticals

Drug Profile

Research programme: siRNA hepatitis therapeutics - Alnylam Pharmaceuticals

Alternative Names: Sirna-034; Sirna-AV34

Latest Information Update: 16 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sirna Therapeutics
  • Class Small interfering RNA
  • Mechanism of Action RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 06 Mar 2014 Alnylam Pharmaceuticals acquires Sirna Therapeutics
  • 30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co
  • 22 Jun 2005 Preclinical data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the Viral infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top